At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 257 enrolled
Drug / intervention
Oxaliplatin +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
In Brief
A Phase 2 clinical trial evaluating Oxaliplatin, Leucovorin Calcium, and 6 other interventions for Adenocarcinoma of the Gastroesophageal Junction and Esophageal Cancer. Completed, enrolled 257 participants across 68 sites.
Detailed Summary
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment. PURPOSE: This randomized phase II trial is studying PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartJul 2011
Primary CompletionNov 2015
Study CompletionApr 2023
TodayJul 2026
First PostedApr 11, 2011
Enrollment StartJul 1, 2011
Primary CompletionNov 1, 2015
Study CompletionApr 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.2 years ago
Interventions
Oxaliplatindrug
Given IV
Leucovorin Calciumdrug
Given IV
Fluorouracildrug
Given IV
Carboplatindrug
Given IV
Paclitaxeldrug
Given IV
Positron Emission Tomographyprocedure
Undergo PET/CT scan
Computed Tomographyprocedure
Undergo PET/CT scan
Radiation Therapyradiation
Undergo RT